Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Single-Dose, Parallel-Controlled Clinical Study to Compare the Pharmacokinetic Similarity Between QL1209 (Perjeta® Biosimilar Candidate) and Perjeta® (Pertuzumab) in Healthy Male Participants

NCT07861139 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07861139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07861139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Single-Dose, Parallel-Controlled Clinical Study to Compare the Pharmacokinetic Similarity Between QL1209 (Perjeta® Biosimilar Candidate) and Perjeta® (Pertuzumab) in Healthy Male Participants
Lead sponsor
Qilu Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
September 30, 2027
Enrollment
80 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer